Aktiechat - investeringstips

	11/5 17:09 af Solsen	Mr. Winkel. You mention more often the potential in Humax TF and se the possibilities in this antibody. Could you give us more on why you become more and more optimistic. Do w e still have to wait to the end of the year to se data ?
	11/5 17:08 af Jan Van de Winkel	The next clinical results to look for beyond daratumumab could be tisotumab vedotin near the end of the year. We are also pushing HuMax-AXL towards the clinic in the second half of the year. We will give goals for 2017 later this year.
	11/5 17:06 af MrEbbe	First of all congrats with the result of 1Q. It seems to me that the 4Q will be relatively quiet regarding to results of your research. What can we expect from Q1 and Q2, of 2017?
	11/5 17:05 af Jan Van de Winkel	We have been delighted with the launch and the rapid uptake so far, with over 100 mn USD in sales in Q1, but it is early days and we have limited data to rely on so far when guiding.
	11/5 17:05 af Jan Van de Winkel	this is based on Genmab's estimated sales number for DARZALEX of 400-450 mn USD...
	11/5 17:04 af Jan Van de Winkel	We increased the guidance on April 20th, increasing the royalty expectations for DARZALEX to around DKK 325 mn....
	11/5 17:03 af Helge Larsen/PI-redaktør	You have a conservative guiding for 2016. Can you tell us more about this.
	11/5 17:03 af Jan Van de Winkel	these were just some of the highlights!
	11/5 17:02 af Jan Van de Winkel	..and we announced plans for combination treatment of dara with Roche's atezolizumab in both MM and in a solid cancer....
	11/5 17:02 af Jan Van de Winkel	we received a positive recommendation for daratumumab in the EU by the CHMP...
	11/5 17:02 af Jan Van de Winkel	...we had a very exciting readout in a key Phase 3 study - CASTOR - daratumumab in combination with Velcade.....
	11/5 17:01 af Jan Van de Winkel	..we remain very well capitalized with around 3.5 bn DKK cash position at the end of the quarter...and then...
	11/5 17:00 af Jan Van de Winkel	...expenses increased due to investment in our pipeline as previously indicated...
	11/5 17:00 af Jan Van de Winkel	The revenue was driven by Daratumumab with DARZALEX royalty at 83 mn DKK and the 34 mn DKK milestone....
	11/5 16:59 af Helge Larsen/PI-redaktør	Great. First of all let me just congratulate on the great results for Q1 . Can you give us a short-term update on key figures and important events in Q1.
	11/5 16:58 af Jan Van de Winkel	We look forward to your questions....
	11/5 16:58 af Helge Larsen/PI-redaktør	Jan van de Winkel and David Eatwell. Welcome to the Q & A here on the ProInvestor. We are very happy that you are back in here and ready to answer questions from our investors.
	11/5 16:57 af Jan Van de Winkel	I am here with David Eatwell our CFO and look forward to a stimulating and energizing session.
	11/5 16:49 af Helge Larsen/PI-redaktør	In 10 minutes we begin the online Q&A with Genmab.
	11/5 16:40 af Helge Larsen/PI-redaktør	This session starts in 20 minutes.